JP2023534720A5 - - Google Patents
Info
- Publication number
- JP2023534720A5 JP2023534720A5 JP2023504330A JP2023504330A JP2023534720A5 JP 2023534720 A5 JP2023534720 A5 JP 2023534720A5 JP 2023504330 A JP2023504330 A JP 2023504330A JP 2023504330 A JP2023504330 A JP 2023504330A JP 2023534720 A5 JP2023534720 A5 JP 2023534720A5
- Authority
- JP
- Japan
- Prior art keywords
- intron
- antisense oligonucleotide
- sequence
- seq
- target region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020902550A AU2020902550A0 (en) | 2020-07-22 | Compositions and methods for treating disorders associated with loss-of-function mutations in SCN2A | |
| AU2020902550 | 2020-07-22 | ||
| PCT/AU2021/050788 WO2022016222A1 (en) | 2020-07-22 | 2021-07-22 | Compositions and methods for treating disorders associated with loss-of-function mutations in scn2a |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023534720A JP2023534720A (ja) | 2023-08-10 |
| JP2023534720A5 true JP2023534720A5 (enExample) | 2024-07-18 |
Family
ID=79729542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504330A Pending JP2023534720A (ja) | 2020-07-22 | 2021-07-22 | Ｓｃｎ２ａ中の機能喪失変異に関連する障害を処置するための組成物及び方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230272387A1 (enExample) |
| EP (1) | EP4185697A4 (enExample) |
| JP (1) | JP2023534720A (enExample) |
| KR (1) | KR20230095056A (enExample) |
| CN (1) | CN116368227A (enExample) |
| AU (1) | AU2021311137A1 (enExample) |
| BR (1) | BR112023000988A2 (enExample) |
| CA (1) | CA3186629A1 (enExample) |
| CL (1) | CL2023000208A1 (enExample) |
| CO (1) | CO2023001922A2 (enExample) |
| EC (1) | ECSP23012641A (enExample) |
| IL (1) | IL299999A (enExample) |
| MX (1) | MX2023000907A (enExample) |
| PE (1) | PE20230982A1 (enExample) |
| WO (1) | WO2022016222A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4473113A4 (en) * | 2022-02-04 | 2026-03-25 | Praxis Prec Medicines Inc | TREATMENT METHODS FOR DISORDERS RELATED TO SCN2A |
| KR20250180156A (ko) | 2024-06-21 | 2025-12-31 | 중앙대학교 산학협력단 | 뇌전증의 예방 또는 치료용 조성물, 및 뇌전증 치료제 스크리닝 방법과 이의 조성물 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1252330T1 (de) * | 1999-11-26 | 2003-11-27 | Mcgill University, Montreal | Loci der idiopathischen epilepsie, mutationen derselben und verfahren zu deren verwendung zur feststellung, prognose und behandlung von epilepsie |
| EP1268856A2 (de) * | 2000-04-07 | 2003-01-02 | Epigenomics AG | Detektion von snp's und cytosin-methylierungen |
| AU2001276919A1 (en) * | 2000-07-13 | 2002-01-30 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the mmp13 gene |
| CA2541836A1 (en) * | 2003-10-13 | 2005-04-21 | Bionomics Limited | A diagnostic method for neonatal or infantile epilepsy syndromes |
| CN101148665A (zh) * | 2005-12-05 | 2008-03-26 | 广州医学院第二附属医院 | 钠离子通道scn1a基因突变及基因突变检测方法和用途 |
| WO2010151671A2 (en) * | 2009-06-24 | 2010-12-29 | Curna, Inc. | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
| EP2490699A1 (en) * | 2009-10-20 | 2012-08-29 | Santaris Pharma A/S | Oral delivery of therapeutically effective lna oligonucleotides |
| US20150141320A1 (en) * | 2012-05-16 | 2015-05-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
| CN109843914B (zh) * | 2016-07-06 | 2024-03-15 | 沃泰克斯药物股份有限公司 | 用于治疗疼痛相关病症的材料和方法 |
| KR20190030833A (ko) * | 2017-09-15 | 2019-03-25 | 가톨릭대학교 산학협력단 | 신장암 환자의 예후 진단 및 치료 전략 결정용 연령 특이적 마커 |
| HUE070436T2 (hu) * | 2017-10-23 | 2025-06-28 | Stoke Therapeutics Inc | Antiszensz oligomerek nonszensz-mediált RNS-lebomláson alapuló állapotok és betegségek kezelésére |
| US11713463B2 (en) * | 2018-01-17 | 2023-08-01 | The Florey Institute Of Neuroscience And Mental Health | Compositions and methods for increasing expression of SCN2A |
| BR112021003224A2 (pt) * | 2018-08-20 | 2021-07-20 | Rogcon, Inc. | oligonucleotídeos antissentido direcionados a scn2a para o tratamento de encefalopatias por scn1a |
| US20220090087A1 (en) * | 2019-01-23 | 2022-03-24 | The Florey Institute Of Neuroscience And Mental Health | Antisense oligonucleotides targeting scn2a retained introns |
-
2021
- 2021-07-22 KR KR1020237005996A patent/KR20230095056A/ko active Pending
- 2021-07-22 EP EP21845305.8A patent/EP4185697A4/en active Pending
- 2021-07-22 CA CA3186629A patent/CA3186629A1/en active Pending
- 2021-07-22 MX MX2023000907A patent/MX2023000907A/es unknown
- 2021-07-22 PE PE2023000101A patent/PE20230982A1/es unknown
- 2021-07-22 AU AU2021311137A patent/AU2021311137A1/en active Pending
- 2021-07-22 US US18/005,800 patent/US20230272387A1/en active Pending
- 2021-07-22 JP JP2023504330A patent/JP2023534720A/ja active Pending
- 2021-07-22 BR BR112023000988A patent/BR112023000988A2/pt unknown
- 2021-07-22 WO PCT/AU2021/050788 patent/WO2022016222A1/en not_active Ceased
- 2021-07-22 IL IL299999A patent/IL299999A/en unknown
- 2021-07-22 CN CN202180064122.5A patent/CN116368227A/zh active Pending
-
2023
- 2023-01-20 CL CL2023000208A patent/CL2023000208A1/es unknown
- 2023-02-21 CO CONC2023/0001922A patent/CO2023001922A2/es unknown
- 2023-02-22 EC ECSENADI202312641A patent/ECSP23012641A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Morihiro et al. | Biological applications of xeno nucleic acids | |
| JP7478923B2 (ja) | シュードウリジン化のための核酸分子 | |
| WO2020196662A1 (ja) | 二本鎖核酸複合体及びその使用 | |
| WO2020198509A2 (en) | Modified oligonucleotides with increased stability | |
| JP6813506B2 (ja) | レーバー先天性黒内障のためのオリゴヌクレオチド療法 | |
| JP2021533804A5 (enExample) | ||
| TW201726918A (zh) | 抑制lpa之基因表現之組合物及方法 | |
| JP2023534720A5 (enExample) | ||
| WO2016097212A1 (en) | Targeted rna editing | |
| JP2016530882A5 (enExample) | ||
| JP2011520444A5 (enExample) | ||
| CN105008533A (zh) | 嵌合单链反义多核苷酸和双链反义试剂 | |
| WO2022217366A1 (en) | Modified oligonucleotides for the treatment of duchenne muscular dystrophy | |
| JP2023518268A5 (enExample) | ||
| CN113286887A (zh) | 用于肌营养不良蛋白外显子跳跃的双特异性反义低聚核苷酸 | |
| BR112020010090A2 (pt) | oligonucleotídeo gapmer, sal farmaceuticamente aceitável do mesmo, conjugado, composição farmacêutica e uso dos mesmos | |
| JP2024543000A (ja) | 操作されたｒｎａ | |
| KR20250125967A (ko) | 진보된 rna 표적화 (arnatar) | |
| US20250313832A1 (en) | Compositions for treating syngap-1 related neurodevelopmental disorders | |
| JP2024522272A5 (enExample) | ||
| JP2024542738A5 (enExample) | ||
| JP2023534720A (ja) | Ｓｃｎ２ａ中の機能喪失変異に関連する障害を処置するための組成物及び方法 | |
| JPWO2019004420A1 (ja) | ヘテロ二本鎖型ａｎｔｉｍｉＲ | |
| WO2020171149A1 (ja) | ヘテロ核酸の最適ｐｓ修飾パターン | |
| BR112020012427A2 (pt) | oligonucleotídeo, sal farmaceuticamente aceitável, conjugado, composição farmacêutica, processo para a fabricação de um oligonucleotídeo, oligonucleotídeo fabricado e invenção |